यह प्रोटोकॉल उन वयस्कों पर लागू होता है जिनमें एनाप्लास्टिक एस्ट्रोसाइटोमा, CNS WHO ग्रेड 3 है, और जिनमें आणविक परीक्षण IDH म्यूटेशन (IDH-वाइल्डटाइप) की अनुपस्थिति की पुष्टि करता है। यह आणविक निष्कर्ष इस जनसंख्या के लिए उपचार दृष्टिकोण का एक प्रमुख निर्धारक है।
पूर्ण प्रोटोकॉल विवरण — सभी घटक, अनुक्रमण, पात्रता मानदंड — नीचे संरचित नियम के माध्यम से उपलब्ध हैं।
DOI: 10.1093/neuonc/noab279
People with astrocytomas, IDH-wildtype, CNS WHO grade 2 or 3 may be treated according to recommendations for glioblastoma, IDH-wildtype, CNS WHO grade 4 found in this guideline (Type: informal consensus; Evidence quality: very low; Strength of recommendation: weak).
Concurrent TMZ and RT should be offered to people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).
Six months of adjuvant TMZ should be offered to people with newly diagnosed glioblastoma, IDH-wildtype, CNS WHO grade 4 who have received concurrent RT plus TMZ (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: strong).
Alternating electric field therapy may be added to adjuvant TMZ in people with newly diagnosed supratentorial glioblastoma, IDH-wildtype, CNS WHO grade 4 who have completed chemoradiation therapy (Type: evidence-based, benefits outweigh harms; Evidence quality: moderate; Strength of recommendation: weak).
View source ↗